Physician profile
Sai Konduru
NPI 1972714889
$1,858.98
in general payments reported to CMS, 2019-2025
15 companies · $19.63 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $284 · 2021: $317 · 2022: $341 · 2023: $119 · 2025: $19.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $680.26 | 2019-2020 | |
| Boston Scientific Corporation | $312.15 | 2019-2025 | Farapulse |
| Medtronic, INC. | $257.71 | 2021-2023 | Micra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $192.51 | 2019-2022 | |
| Biosense Webster, INC. | $91.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $69.64 | 2019-2022 | |
| Amgen INC. | $67.34 | 2019-2020 | |
| Atricure, INC. | $66.53 | 2019 | |
| Pfizer INC. | $38.06 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $22.38 | 2020 | |
| Merck Sharp & Dohme LLC | $17.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.29 | 2019 | |
| Ge Healthcare | $12.92 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $12.17 | 2019 | |
| Bardy Diagnostics, INC. | $2.76 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sai Konduru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.